<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489059</url>
  </required_header>
  <id_info>
    <org_study_id>CA220-007</org_study_id>
    <nct_id>NCT01489059</nct_id>
  </id_info>
  <brief_title>Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma</brief_title>
  <official_title>A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of interleukin-21 (IL-21)
      and Ipilimumab in subjects with melanoma is safe, and provide preliminary information on the
      clinical benefits of the combination compared with Ipilimumab alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: Part 1 Dose Escalation Phase: Non-randomized; Part 2 Cohort Expansion Phase:
      Randomized
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part1 (Dose Escalation): The Maximum tolerated dose (MTD) of BMS-982470 using 2 distinct schedules when administered in combination with Ipilimumab</measure>
    <time_frame>Within the first 63 days</time_frame>
    <description>Based on the dose-limiting toxicity (DLT) rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Cohort Escalation): Safety and tolerability of the MTD dose for each of the schedules</measure>
    <time_frame>84 days on treatment</time_frame>
    <description>Based on medical review of AE reports and the results of vital sign measurements, physical examinations, medical history, and clinical laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of BMS-982470 in combination with Ipilimumab as measured by objective response</measure>
    <time_frame>Baseline (Day 1), End of Treatment (EOT) [3 weeks after last dose of Ipilimumab], 3 and 6 months Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the last quantifiable concentration [AUC(0-T)] of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval [AUC(TAU)] of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum observed serum concentration (Cmax) of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Cmin) of BMS-982470 and Ipilimumab</measure>
    <time_frame>1 time point each 3-week Cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of maximum observed serum concentration (Tmax) of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum half-life (T-HALF) of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT) of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of BMS-982470 and Ipilimumab</measure>
    <time_frame>20 time points during Lead-In Cycle; Up to 11 time points during Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BMS-984270 and Ipilimumab Anti-Drug Antibodies</measure>
    <time_frame>Up to 6 months following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort Expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort Expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 3: Ipilimumab monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort Expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-982470 (recombinant interleukin-21)</intervention_name>
    <description>Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response</description>
    <arm_group_label>Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-982470 (recombinant interleukin-21)</intervention_name>
    <description>Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response</description>
    <arm_group_label>Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-982470 (recombinant interleukin-21)</intervention_name>
    <description>Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response</description>
    <arm_group_label>Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-982470 (recombinant interleukin-21)</intervention_name>
    <description>Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response</description>
    <arm_group_label>Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response</description>
    <arm_group_label>Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
    <arm_group_label>Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response</description>
    <arm_group_label>Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab</arm_group_label>
    <arm_group_label>Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response</description>
    <arm_group_label>Part 2 - Arm 3: Ipilimumab monotherapy</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Unresectable Stage III or Stage IV melanoma

          -  Part 1 Dose Escalation: Prior melanoma treatment allowed except for the following:
             ipilimumab, BMS-982470 (rIL-21), anti-Programmed Death-1 (anti-PD-1), anti-programmed
             death-ligand 1 (anti-PD-L1), anti-PD-L2 or anti-CD137

          -  Part 2 Cohort expansion: Prior treatment for melanoma is not allowed, except for
             adjuvant therapy with interferon alpha or melanoma vaccines which are permitted

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)

          -  Normal liver function tests

        Exclusion Criteria:

          -  Part 1 Dose escalation: subjects with ≤ 2 brain metastases of stable size, ≥ 4 weeks
             post-radiation treatment, and off steroids are allowed

          -  Part 2 Cohort expansion: subjects with known or suspected brain metastases and uveal
             melanoma are excluded

          -  Autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Research Associates, Pllc D/B/A</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucla Hematology/Oncology.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Inst, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin And Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Louisville Medical Center, Inc., Dba</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Can Cnt</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

